Anemia frequency increases as CKD progresses, as is well-known [51–55], but the percentage of patients with hemoglobin above 10.6 g/dl (in CKD stages IV-V) slightly increased in the Nephrocare group, and 17.9% received erythropoietin. This evidence concerns the gene EPO and chronic kidney disease.